Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate by Edgar Linden-Castro, Marcela Pelayo-Nieto, Alejandro Alias-Melgar, Daniel Espinosa-Perezgrovas, Ivan Ramirez-Galindo, Gabriel Catalan-Quinto

“…We report the case of a 64-year-old patient with ductal adenocarcinoma of the prostate, which progresses to castration-resistant prostate cancer, that was treated with abiraterone acetate with good clinical response, to our knowledge, the first case of ductal adenocarcinoma of the prostate in treatment with abiraterone acetate.…”
Get full text

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings by Armen Aprikian, Amit Bahl, Aurelius Omlin, Giulia Baciarello, Abhiroop Chakravarty, Prashanth Kondaparthi, Georgia Gourgioti, Thomas McLean, Alexis Serikoff, Andrew Chilelli

Get full text

New Therapeutics to Treat Castrate-Resistant Prostate Cancer by Ömer Acar, Tarık Esen, Nathan A. Lack

“…In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. …”
Get full text

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region by P. G. Berezin, V. V. Milovanov, A. A. Ivannikov, V. A. Kuleshkov, K. M. Nyushko

“…The administration of enzalutamide (in 2 cases) and abiraterone acetate (in 1 case) at the stage of resistance to castration therapy allowed to obtain a complete “response” from visceral lesions, stabilise bone metastatic foci and increase the life expectancy of patients.…”
Get full text

Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer by Manish Kohli, Rui Qin, Rafael Jimenez, Scott M. Dehm

“…Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from “bench to bed-side” has resulted in an enlarging repertoire of novel and traditional drug choices now available for use in advanced prostate cancer therapeutics, which has had a positive clinical impact in prolonging longevity and quality of life of advanced prostate cancer patients. …”
Get full text

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER by A. A. Kostin, A. G. Muradyan, A. O. Tolkachev, S. V. Popov

“…Currently, there are six effective methods of treatment of metastatic castration-refractory prostate cancer (mCRPC): effects on androgenic stimulation (abiraterone acetate, enzalutamide); chemotherapy with drugs from the taxane group (docetaxel, cabazitaxel); immunotherapy (Sipuleucel-T), radionuclide therapy with Radium-223 chloride (Ksofigo®). 223Ra is a tropic to bone tissue alpha emitter, which, due to its high linear energy transfer and short transmission distance, provides an enhanced localized antitumor effect due to higher energy delivery. …”
Get full text

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis by Renliang Yi, Baoxin Chen, Peng Duan, Chanjiao Zheng, Huanyu Shen, Qun Liu, Chen Yuan, Weilin Ou, Zhiheng Zhou

“…New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). …”
Get full text

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer by Yi Wu, Xiang Liu, Shaoxian Chen, Fen Fang, Feng Shi, Yuwei Xia, Zehong Yang, Daiying Lin

“…ObjectiveTo establish a combined radiomics-clinical model for the early prediction of a prostate-specific antigen(PSA) response in patients with metastatic castration-resistant prostate cancer(mCRPC) after treatment with abiraterone acetate(AA).MethodsThe data of a total of 60 mCRPC patients from two hospitals were retrospectively analyzed and randomized into a training group(n=48) or a validation group(n=12). …”
Get full text